We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


genOway Improves its Growth With Major Japanese Biopharmaceutical Companies

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "genOway Improves its Growth With Major Japanese Biopharmaceutical Companies"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
genOway announces strong growth of its business with major Japanese biopharmaceutical companies

The three Japanese biopharmaceutical companies, now customers of genOway, rank among the top ten of the nation’s biopharmaceutical industry. The amount of the active contracts just exceeded €400,000.

These agreements cover the development and delivery of genetically modified animal models and particularly humanized models dedicated to pharmaceutical compound testing. Other contractual details were not disclosed.

Alexandre Fraichard, CEO of genOway, declared: “Japanese biopharmaceutical industry is beginning to show signs of recovery. We were able to drop back on the market since the second half of 2009 and are very pleased that three of the largest Japanese biopharmaceutical companies now make use of our services and added value solutions. It is very important for us to attend sustainably this market, the second in size after the United States. In fact, we are very confident in signing several contracts in Japan in the coming trimesters.”